The observation that treatment with SLN-TMZ increases expression of IL-17A without affecting expression of IL-10 suggests that this treatment may also exert positive effects on the anti-tumor immune response by increasing the TH17/Treg cell ratio. This evidence concerns the gene IL10 and neoplasm.